Otenzepad

{{short description|Drug}}

{{Drugbox

| image = 180px

| caption = Structure of Otenzepad

| CAS_number = 102394-31-0

| CAS_number_Ref = {{Cascite|correct|CAS}}

| PubChem = 107867

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = OM7J0XAL0S

| ChEBI = 111174

| ChEMBL = 17045

| ChemSpiderID = 97004

| IUPHAR_ligand = 309

| IUPAC_name = 11-[2-[2-(diethylaminomethyl)piperidin-1-yl]acetyl]-5H-pyrido[2,3-b][1,4]benzodiazepin-6-one

| C=24 | H=31 | N=5 | O=2

| SMILES = CCN(CC)CC1CCCCN1CC(=O)N2C3=CC=CC=C3C(=O)NC4=C2N=CC=C4

| StdInChI=1S/C24H31N5O2/c1-3-27(4-2)16-18-10-7-8-15-28(18)17-22(30)29-21-13-6-5-11-19(21)24(31)26-20-12-9-14-25-23(20)29/h5-6,9,11-14,18H,3-4,7-8,10,15-17H2,1-2H3,(H,26,31)

| StdInChIKey = UBRKDAVQCKZSPO-UHFFFAOYSA-N

|bioavailability = 45% (oral){{cite web|url=https://drugs.ncats.io/substance/WW6A9TFL2C |website=National Centre for Advancing Translational Sciences |title=Otenzepad |access-date=10 June 2021}}

|routes_of_administration=oral

|elimination_half-life=2.5h}}

Otenzepad is a competitive muscarinic receptor antagonist that is relatively selective at the M2 receptor. It was investigated as a treatment for arrhythmia and bradycardia due to its cardioselectivity but research ceased after stage III clinical trials. The drug was originally developed by the German pharmaceutical company, Boehringer Ingelheim Pharma KG.